Document is current
Any future updates will be listed below
-
Authors
Chanoch-Myers, Rony
Hara, Toshiro https://orcid.org/0000-0002-4389-3393
Greenwald, Alissa C.
Hoefflin, Rouven
Bussema, Lillian https://orcid.org/0000-0001-5469-3816
Weisman, Hannah R. https://orcid.org/0009-0008-0493-9265
Nieblas-Bedolla, Edwin https://orcid.org/0000-0001-5879-1800
Gurramkonda, Jahnavi https://orcid.org/0009-0007-3374-606X
Bekezhankyzy, Zhibek
Jucht, Alexander https://orcid.org/0009-0004-9384-804X
Calvo Fernández, Ester
Spitzer, Avishay https://orcid.org/0000-0001-6551-9338
Fung, Jeremy Man Hon
Chiara, Biella
Al-Holou, Wajd N.
Camelo-Piragua, Sandra
Behnan, Jinan https://orcid.org/0000-0001-5780-0971
Galli, Rossella https://orcid.org/0000-0001-9023-7033
Wakimoto, Hiroaki https://orcid.org/0000-0001-8225-241X
Suvà, Mario L.
Tirosh, Itay https://orcid.org/0000-0001-5477-2987
- License Information
-
More Information
Article History
Received: 1 November 2024
Accepted: 22 February 2026
First Online: 17 March 2026
Competing interests
: I.T. is an advisory board member of Immunitas Therapeutics, and a scientific co-founder, equity holder and advisory board member of Cellyrix Therapeutics. M.L.S. is an equity holder, scientific co-founder, and advisory board member of Immunitas Therapeutics. The remaining authors declare no competing interests.
